Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.
Decensi
A
A
Department of Medical Oncology, II, National Institute for Cancer Research, Genoa, Italy.
Bruno
S
S
Costantini
M
M
Torrisi
R
R
Curotto
A
A
Gatteschi
B
B
Nicolò
G
G
Polizzi
A
A
Perloff
M
M
Malone
W F
WF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004273:DNA, Neoplasm / Q000032:analysis*; D003623:Dark Adaptation / Q000187:drug effects; D005240:Feasibility Studies; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004273:DNA, Neoplasm; D017313:Fenretinide